Provided by Tiger Trade Technology Pte. Ltd.

Caribou Biosciences

1.66
+0.05003.11%
Post-market: 1.680.0191+1.15%19:30 EDT
Volume:1.16M
Turnover:1.93M
Market Cap:177.62M
PE:-1.54
High:1.69
Open:1.64
Low:1.62
Close:1.61
52wk High:3.54
52wk Low:1.38
Shares:107.00M
Float Shares:102.16M
Volume Ratio:1.13
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0751
EPS(LYR):-1.5900
ROE:-78.27%
ROA:-36.84%
PB:1.81
PE(LYR):-1.04

Loading ...

Lytix Biopharma Names Timothy Herpin Chief Business Officer

Reuters
·
Aug 18

Caribou Biosciences is Maintained at Buy by B of a Securities

Dow Jones
·
Aug 15

BofA Adjusts Price Target on Caribou Biosciences to $5 From $6

MT Newswires Live
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Aug 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (CRBU), Bristol-Myers Squibb (BMY) and Schrodinger (SDGR)

TIPRANKS
·
Aug 14

Caribou Biosciences Q2 Basic EPS USD -0.24

THOMSON REUTERS
·
Aug 14

Caribou Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate

Benzinga Earnings
·
Aug 14

Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million

Reuters
·
Aug 14

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Caribou Biosciences, Inc. Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Caribou Biosciences Inc Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Caribou Biosciences CEO Joins H.C. Wainwright Cell Therapy Conference Fireside Chat

Reuters
·
Jun 29

Caribou Biosciences Shareholders Decide Key Governance Matters

TIPRANKS
·
Jun 19

Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meeting

Reuters
·
Jun 19

Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

TIPRANKS
·
Jun 12

Caribou Biosciences presents ANTLER trial results at EHA

TIPRANKS
·
Jun 11

Caribou Biosciences Potential Non-Hodgkin Lymphoma Cell Therapy Shows 'Durable' Responses

MT Newswires Live
·
Jun 11

Caribou Biosciences posts EHA presentation on vispa-cel durability data in B-cell lymphoma trial

Reuters
·
Jun 11

Caribou says off-the-shelf CAR-T vispa-cel posts 82% response rate in second-line LBCL study

Reuters
·
Jun 11